Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m. ET and was down by as much as 11.8% earlier in the day. The move comes as the S&P ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.

"Recursion's decade-long investment in AI is driving a decisive, data-led portfolio strategy," said Chris Gibson, Co-Founder and CEO of Recursion. "We are prioritizing high-potential programs to ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

"Recursion's decade-long investment in AI is driving a decisive, data-led portfolio strategy," said Chris Gibson, Co-Founder and CEO of Recursion. "We are prioritizing high-potential programs to ...

Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss. Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date. The clinical ...

In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.

Explore Recursion Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RXRX. Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's ...

Discover how a custom RAG MCP server redefines AI coding with private knowledge bases, scalability, and unmatched accuracy.